Published in Therapeutic Advances in Urology, this IRB-approved study surpasses prior research by evaluating 299 patients across four institutions, confirming Himplant's reliable gains in size, safety, and satisfaction. BEVERLY HILLS, Calif. , Oct.
31, 2024 /PRNewswire/ -- Himplant , a leader in cosmetic penile enhancement, announces a landmark study demonstrating Himplant's substantial success in delivering effective results in penile size enhancement and patient satisfaction. The study, titled "A Multi-Institutional Update on Surgical Outcomes After Penile Silicone Sleeve Implantation," is an extensive analysis, covering 299 patients with an average age of 42.5 years and an average follow-up period of 11.
6 months. In comparison to previous studies, this research reveals lower complication rates, with infection at 1.3%, seroma at 2.
0%, and erosion at 5.0%, reinforcing Himplant's strong profile. Patients in the study experienced an average 50% increase in flaccid length (adding 4.
1 cm) and a 37% increase in girth (adding 3.4 cm), highlighting a significant improvement in cosmetic outcomes. Notably, the study also reports a minimal need for revision surgeries, emphasizing Himplant's durability and stable results.
Key findings include: Significant size enhancement: Patients achieved an average increase of 4.1 cm in length and 3.4 cm in girth, a 50% and 37% improvement, respectively.
Fewer complications: Infection rates were reduced to 1.3%, with seroma at 2.0%—improving upon .